論文

査読有り 国際誌
2014年11月

Features of ovarian cancer in Lynch syndrome (Review).

Molecular and clinical oncology
  • Kanako Nakamura
  • Kouji Banno
  • Megumi Yanokura
  • Miho Iida
  • Masataka Adachi
  • Kenta Masuda
  • Arisa Ueki
  • Yusuke Kobayashi
  • Hiroyuki Nomura
  • Akira Hirasawa
  • Eiichiro Tominaga
  • Daisuke Aoki
  • 全て表示

2
6
開始ページ
909
終了ページ
916
記述言語
英語
掲載種別
研究論文(学術雑誌)

Lynch syndrome is a hereditary ovarian cancer with a prevalence of 0.9-2.7%. Lynch syndrome accounts for 10-15% of hereditary ovarian cancers, while hereditary breast and ovarian cancer syndrome accounts for 65-75% of these cancers. The lifetime risk for ovarian cancer in families with Lynch syndrome is ~8%, which is lower than colorectal and endometrial cancers, and ovarian cancer is not listed in the Amsterdam Criteria II. More than half of sporadic ovarian cancers are diagnosed in stage III or IV, but ≥80% of ovarian cancers in Lynch syndrome are diagnosed in stage I or II. Ovarian cancers in Lynch syndrome mostly have non-serous histology and different properties from those of sporadic ovarian cancers. A screening method for ovarian cancers in Lynch syndrome has yet to be established and clinical studies of prophylactic administration of oral contraceptives are not available. However, molecular profiles at the genetic level indicate that ovarian cancer in Lynch syndrome has a more favorable prognosis than sporadic ovarian cancer. Inhibitors of the phosphatidylinositol 3-kinase/mammalian target of the rapamycin pathway and anti-epidermal growth factor antibodies may have efficacy for the disease. To the best of our knowledge, this is the first review focusing on ovarian cancer in Lynch syndrome.

リンク情報
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/25279173
PubMed Central
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4179837
ID情報
  • ISSN : 2049-9450
  • PubMed ID : 25279173
  • PubMed Central 記事ID : PMC4179837

エクスポート
BibTeX RIS